Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab

References

• Boissier MC Semerano L Challal S Saidenberg-Kermanac’h N Falgarone G Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction J Autoimmun 2012 39 3 222 228 22704962
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the management of rheumatoid arthritis. 2002 Update Arthritis Rheum 2002 46 2 328 346 11840435
   PubMed Web of Science ®Google Scholar
• Müller N Döring F Klapper M Interleukin-6 and Tumour Necrosis Factor-α differentially regulate lincRNA transcripts in cells of the innate immune system in vivo in human subjects with rheumatoid arthritis Cytokine 2014 68 1 65 68 24721042
   PubMed Web of Science ®Google Scholar
• Feldmann M Maini RN Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001 19 163 196 11244034
   PubMed Web of Science ®Google Scholar
• Alghasham A Rasheed Z Therapeutic targets for rheumatoid arthritis: Progress and promises Autoimmunity 2014 47 2 77 94 24437572
   PubMed Web of Science ®Google Scholar
• Nam JL Winthrop KL van Vollenhoven RF Current evidence for the management of rheumatoid arthritis with biological disease-modifying anti-rheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA Ann Rheum Dis 2010 69 6 976 986 20447957
   PubMed Web of Science ®Google Scholar
• Smolen JS Aletaha D Bijlsma JW T2T Expert Committee Treating rheumatoid arthritis to target: recommendations of an international task force Ann Rheum Dis 2010 69 4 631 637 20215140
   PubMed Web of Science ®Google Scholar
• Schipper LG Vermeer M Kuper HH A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry Ann Rheum Dis 2012 71 6 845 850 22210852
   PubMed Web of Science ®Google Scholar
• Wang J Platt A Upmanyu R IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis BMJ Open 2013 3 8 e003199
   Web of Science ®Google Scholar
• Nishimoto N Interleukin-6 as a therapeutic target in candidate inflammatory diseases Clin Pharmacol Ther 2010 87 4 483 487 20182422
   PubMed Web of Science ®Google Scholar
• Smolen JS Aletaha D Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants Arthritis Rheum 2011 63 1 43 52 21204103
   PubMed Web of Science ®Google Scholar
• Brandão FM Coelho P Pinto P Combe B Tocilizumab – a new step in rheumatoid arthritis treatment Acta Reumatol Port 2010 35 3 302 312 20975633
   PubMed Web of Science ®Google Scholar
• Schoels MM van der Heijde D Breedveld FC Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement Ann Rheum Dis 2013 72 4 583 589 23144446
   PubMed Web of Science ®Google Scholar
• Smolen JS Schoels MM Nishimoto N Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions Ann Rheum Dis 2013 72 4 482 492 23172750
   PubMed Web of Science ®Google Scholar
• Oldfield V1 Dhillon S Plosker GL Tocilizumab: a review of its use in the management of rheumatoid arthritis Drugs 2009 69 5 609 632 19368420
   PubMed Web of Science ®Google Scholar
• Nishimoto N Miyasaka N Yamamoto K Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy Mod Rheumatol 2009 19 1 12 19 18979150
   PubMed Web of Science ®Google Scholar
• Smolen JS Beaulieu A Rubbert-Roth A OPTION Investigators Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 2008 371 9617 987 997 18358926
   PubMed Web of Science ®Google Scholar
• Jones G Sebba A Gu J Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 2010 69 1 88 96 19297346
   PubMed Web of Science ®Google Scholar
• Emery P Keystone E Tony HP IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis 2008 67 11 1516 1523 18625622
   PubMed Web of Science ®Google Scholar
• Kremer JM Blanco R Brzosko M Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year Arthritis Rheum 2011 63 3 609 621 21360490
   PubMed Web of Science ®Google Scholar
• Genovese MC McKay JD Nasonov EL Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 2008 58 10 2968 2980 18821691
   PubMed Web of Science ®Google Scholar
• Yazici Y Curtis JR Ince A Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study Ann Rheum Dis 2012 71 2 198 205 21949007
   PubMed Web of Science ®Google Scholar
• Maini RN Taylor PC Szechinski J CHARISMA Study Group Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 2006 54 9 2817 2829 16947782
   PubMed Web of Science ®Google Scholar
• Dougados M Kissel K Sheeran T Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann Rheum Dis 2013 72 1 43 50 22562983
   PubMed Web of Science ®Google Scholar
• Gabay C Emery P van Vollenhoven R ADACTA Study Investigators Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet 2013 381 9877 1541 1550 23515142
   PubMed Web of Science ®Google Scholar
• Nishimoto N Hashimoto J Miyasaka N Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Ann Rheum Dis 2007 66 9 1162 1167 17485422
   PubMed Web of Science ®Google Scholar
• Nakashima Y Kondo M Fukuda T Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data Mod Rheumatol 2014 24 2 258 264 24593201
   PubMed Web of Science ®Google Scholar
• Nakashima Y Kondo M Harada H Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate Mod Rheumatol 2010 20 4 343 352 20480201
   PubMed Web of Science ®Google Scholar
• Barton JL Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy Patient Prefer Adherence 2009 3 335 344 20016797
   PubMed Web of Science ®Google Scholar
• Chilton F Collett RA Treatment choices, preferences and decision-making by patients with rheumatoid arthritis Musculoskeletal Care 2008 6 1 1 14 17726671
   PubMedGoogle Scholar
• Williams EL Edwards CJ Patient preferences in choosing anti-TNF therapies-R1 Rheumatology (Oxford) 2006 45 12 1575 1576 17085468
   PubMed Web of Science ®Google Scholar
• Zhang X Georgy A Rowell L Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects Int J Clin Pharmacol Ther 2013 51 6 443 455 23547848
   PubMed Web of Science ®Google Scholar
• Zhang X Chen YC Fettner S Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis Int J Clin Pharmacol Ther 2013 51 8 620 630 23782588
   PubMed Web of Science ®Google Scholar
• Ohta S Tsuru T Terao K Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study) J Clin Pharmacol 2014 54 1 109 119 24115082
   PubMed Web of Science ®Google Scholar
• Burmester GR Rubbert-Roth A Cantagrel A A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) Ann Rheum Dis 2014 73 1 69 74 23904473
   PubMed Web of Science ®Google Scholar
• Ogata A Tanimura K Sugimoto T Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis Arthritis Care Res (Hoboken) 2014 66 3 344 354 23983039
   PubMed Web of Science ®Google Scholar
• Burmester GR Rubbert-Roth A Cantagrel AG A randomized, double-blind, parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional Dmards in patients with moderate to severe RA Arthritis Rheum 2012 64 10 S1075 S1075
   Web of Science ®Google Scholar